Introduction
Splicing of pre-mRNAs removes noncoding introns and generates protein diversity with alternative inclusion or exclusion of certain protein-coding exons or parts of exons. Mutations affecting sequences involved in splicing underlie many genetic diseases, and alternative splicing is often disrupted in acquired diseases like cancer. We will discuss recently published advances in therapeutic strategies to treat diseases arising from splicing defects. More comprehensive discourses on this topic include Hammond and Wood (2011) .
Exon Skipping to Restore the Open Reading Frame
Exon skipping can be achieved with antisense oligonucleotides (AONs) and is a strategy for treating Duchenne muscular dystrophy (DMD) . Of all approaches to modulate splicing, this application is the closest to clinical application. DMD is a severe muscle-wasting disorder caused by mutations in the DMD gene encoding dystrophin that links the cytoskeleton to the extracellular matrix of muscle fibers. Point mutations and frame-shifting deletions lead to premature truncation of protein translation and render the protein nonfunctional. Restoring the reading frame of DMD transcripts could be beneficial, as the resulting internally deleted dystrophins are found in the milder Becker muscular dystrophy. To achieve exon skipping, AONs target specific exons in the pre-mRNA, hide them from the splicing machinery, and cause them to be skipped during the splicing process ( Figure 1A) .
Following preclinical tests in patient-derived cell and animal models, this approach is currently in clinical trials for exon 51 skipping, as this would benefit the largest group of patients. Two AON chemistries have been developed in parallel: 2 0 -Omethyl phosphorothioate AONs (2OMePS) and phosphorodiamidate morpholino oligomers (PMO). Both AONs induce exon 51 skipping and dystrophin restoration at comparable levels after intramuscular injections in DMD patients (44%-97% dystrophin positive fibers, 17%-35% dystrophin levels) (Kinali et al., 2009; van Deutekom et al., 2007) . As systemic treatment is required to target all muscle tissue, the 2OMePS AON was delivered subcutaneously in phase I/II studies at different doses by five weekly injections. This treatment resulted in detectable dystrophin in 10 out of 12 treated patients in 60%-100% of fibers in a dose-dependent manner. Levels up to 15.6% of normal dystrophin level were detected in biopsies taken 1 month after the last treatment, whereas in pretreatment biopsies taken from three patients, up to 7% of fibers were positive and dystrophin levels were, at most, 2% of normal. All patients then entered an open label extension study in which they received weekly treatment with the highest dose (6 mg/kg). After 12 weeks, a modest improvement in the 6 min walk test distance was observed for most patients (Goemans et al., 2011) . Lacking a placebo group and the sample size to assess statistical significance for the walking test improvement, this finding should be interpreted with caution. In terms of side effects, injection site reactions are common for 2OMePS AONs and were indeed observed in all patients. Several additional trials with this AON are currently ongoing, including a double-blind placebocontrolled trial.
For the PMO AON, six different doses (up to 20 mg/kg) were infused intravenously weekly for 12 weeks. Pretreatment biopsies were taken for all patients and increased dystrophin levels were found in 7 out of 19 patients, including three good responders who showed up to 55% dystrophin positive fibers and 11%-22% of normal dystrophin levels. No effect on muscle function could be detected (Cirak et al., 2011) . A significant decrease in the number of infiltrating T cells was observed in biopsies from patients in the two highest dose groups, suggesting a reduced inflammatory state of the muscle. Further dose optimization is currently ongoing in a recently started trial testing weekly intravenous infusion of higher doses (30 and 50 mg/kg) for 24 weeks (http://www.clinicaltrials.gov/ct2/ results?term=NCT01396239).
The main hurdle for this approach will be its specificity for targeting different mutations, as currently, each AON is considered a different drug by regulatory authorities and thus has to be developed separately. In addition, it will not be feasible to perform large trials for exons affected in small groups of patients. New clinical trial models to assess safety and efficacy for AONs must be developed to allow broad clinical applicability.
Restoration of Cryptic Splicing
Mutations can also introduce aberrant splice sites, resulting in the inclusion or exclusion of an exon or part of an exon.
Hutchinson-Gilford progeria syndrome is a rare autosomaldominant disorder characterized by accelerated aging, growth impairment, and shortened life span, among other symptoms. In most patients, the disease is caused by a mutation in exon 11 of the LMNA gene that introduces a cryptic splice site, resulting in a shortened protein called progerin. Of note, progerin is also produced during normal aging, albeit at lower levels and over a longer time frame. Recently, mice carrying the equivalent of the human mutation were generated that exhibit aspects of the human disease phenotype (Osorio et al., 2011) . PMOs targeting the donor splice site of exon 10 and/or the mutation in exon 11 of the Lmna gene ( Figure 1B ) reduce the production of progerin in cultured fibroblasts derived from the mouse model in a dosedependent manner, with the combination of PMOs targeting the mutation and the donor splice site outperforming single PMOs. Human-specific PMOs yielded similar results in patientderived fibroblasts. For systemic tests, a combination of vivomorpholinos (PMOs covalently linked to an octa-guanidine dendrimer to facilitate uptake by most tissues) targeting exon 10 and exon 11 (6 mg/kg of each AON) were administered intravenously twice weekly to mice for 12 weeks. This treatment ameliorated most of the phenotypes and extended survival from 111 to 155 days. These results bode well for the treatment of this disorder even though the number of patients is low, raising the same challenges for trials discussed for DMD.
Another example of a syndrome often caused by cryptic splicing is ataxia-telangiecatasia, an autosomal recessive disease caused by mutations in the ATM gene. This disorder is characterized by progressive neurodegeneration, immunodeficiency, radiosensitivity, and a high risk for cancer. PMOs linked to an arginine-rich peptide (PPMO, an alternative way to enhance tissue uptake) targeting two prototypic ATM-splicing mutations restored normal splicing and ATM protein production and abrogated radiosensitivity in patient-derived cell lines (Du et al., 2011) . As the most debilitating feature of the disease is the progressive loss of Purkinje cells in the cerebellum, it is crucial that AONs cross the blood-brain barrier. Intravenous injections of high doses (60 mg/kg) of a fluorescently labeled PPMO resulted in green fluorescence throughout the brain, with high expression in the Purkinje cell layer, suggesting that these PPMOs can target the central nervous system, at least in mice (Du et al., 2011) . Followup studies with ATM-targeting PPMOs will be needed to learn their efficacy in terms of functional targeting and dose toleration.
The autosomal recessive Fukuyama congenital muscular dystrophy (FCMD) results from insertion of a SVA (SINE-VNTR-Alu) retrotransposon into the FCMD gene. It was recently shown that this insertion causes aberrant activation of a cryptic donor splice site in the last exon of this gene and an acceptor splice site in the retrotransposon, leading to loss of the distal part of the last exon and inclusion of a retrotransposon-derived exon (Taniguchi-Ikeda et al., 2011) ( Figure 1C) . Consequently, the fukutin protein lacks its C-terminal 38 amino acids and instead contains 129 amino acids derived from the SVA sequence, causing mislocalization of fukutin to the endoplasmic reticulum instead of the Golgi apparatus. It cannot therefore properly glycosylate a-dystroglycan, leading to disrupted interactions with extracellular matrix proteins like laminin. A knockin mouse model containing human exon 10 and the SVA retrotransposon showed the same splicing abnormality and recapitulated the hypoglycosylation of a-dystroglycan. 2OMePS AONs targeting the acceptor or donor splice site or the exonic splicing enhancer of the SVA exon restored normal splicing in cultured cells to some extent, and a cocktail containing AONs targeting each of these sites worked efficiently (Taniguchi-Ikeda et al., 2011) ( Figure 1C ). Local intramuscular and systemic injections of vivo-morpholino counterparts restored splicing and rescued levels of functional fukutin protein. Retrotransposon-induced aberrant splicing has been confirmed for at least two other genetic diseases (autosomal recessive hypercholesterolemia and lipid storage disease with subclinical myopathy) (Taniguchi-Ikeda et al., 2011), and splicing abnormalities have not yet been investigated for other diseases with retrotransposon insertions. It may be that incorporation of retrotransposon sequences into exons is a common disease mechanism for which antisense-mediated exon skipping would provide a potential therapeutic tool.
Tweaking Alternative Splicing
In most cancers, alternative splicing of many genes is disrupted. Some genes can produce both oncogenic and tumor suppressor proteins based on the inclusion or exclusion of specific exons. STAT3, a transcription factor implicated in cytokine and growth factor signaling, is activated via transient phosphorylation of monomers, which then dimerize and translocate to the nucleus. Persistent phosphorylation of STAT3 is observed in the majority of human cancers. There are two main STAT3 isoforms: the full-length STAT3a and STAT3b that lacks part of exon 23 due to an alternative splicing event recognizing an acceptor splice site within exon 23. STAT3b lacks the transactivation domain but can still dimerize with STAT3a and bind to DNA without inducing transcriptional activity. It thus may act in a dominantnegative manner to induce apoptosis and inhibit tumor growth but has recently been shown to also downregulate expression of additional genes involved in proliferation and cancer (Zammarchi et al., 2011) . A PMO targeting the acceptor splice site of STAT3a exon 23 was able to induce a switch from STAT3a to STAT3b ( Figure 1D ) in cultured tumor cell lines, leading to increased cell death for two out of three tested tumor cell lines. In vivo, injections of the vivo-morpholino counterparts of this PMO into implanted tumors were able to bring about a similar switch in STAT3 isoform expression, which resulted in tumor regression, a lower mitotic index, and improved morphology. Knockdown of both isoforms through vivo-morpholino-induced skipping of the out-of-frame exon 6 ( Figure 1D ) did not have any notable effects on tumor growth morphology, apoptosis, and mitosis, in line with the additional functions ascribed to STAT3b (Zammarchi et al., 2011) . This example illustrates how AON-mediated exon skipping can serve both as a tool to elucidate functions of different isoforms and as a therapeutic approach. The biggest hurdle to developing AON-mediated exon skipping as a cancer therapy will be tumor delivery. Intratumor delivery may be the preferred route, as delivery to tumors through systemic administration is difficult. However, unlike the case for many genetic diseases in which a minor increase in protein level is anticipated to be therapeutically beneficial, for cancer, it is crucial that no tumor cells escape treatment. Intratumor delivery will miss cells that have metastasized.
Another disease caused by disrupted alternative splicing is myotonic dystrophy. In myotonic dystrophy type 1, expression of an expanded repeat in transcripts of the DMPK gene leads to aggregates of mRNA that sequester the splicing factor muscleblind-like 1 (MBNL1), resulting in a switch from an adult to a fetal splicing pattern for multiple genes. Rather than using AONs to revert splicing of each and every misspliced transcript, it has been feasible to use PMO and 2OMePS AONs that target repeats to correct the defects. This targeting disrupts the aggregated DMPK transcripts in patient-derived cells and a mouse model containing CUG repeats inserted in the 3 0 UTR of the human actin gene, which leads to similar splicing abnormalities as observed in myotonic dystrophy patients (Mulders et al., 2009; Wheeler et al., 2009) (Figure 1E ). Treatment with these AONs normalized splicing in cultured cells and the mouse model after intramuscular injection . It was recently shown that splicing abnormalities may also occur in polyglutamine diseases such as spinal cerebellar ataxia 3 and Huntington's disease that are caused by shorter CAG repeats (Mykowska et al., 2011) , and that ALS is frequently caused by expanded hexanucleotide repeats (DeJesus-Hernandez et al., 2011). Thus, repeat targeting AONs may be more widely applicable than just for myotonic dystrophy.
Inducing Exon Inclusion
Spinal muscular atrophy is an autosomal recessive disease caused by mutations affecting the SMN1 gene. The homologous SMN2 gene cannot functionally compensate for SMN1 mutations because exon 7 is skipped in the majority of SMN2 transcripts, resulting in an unstable protein. In the absence of SMN1, functional SMN protein is produced only from the 10% of SMN2 transcripts in which exon 7 is included. As the severity of the disease inversely correlates with the number of SMN2 gene copies present, and with the amount of SMN protein produced, increasing the inclusion of exon 7 is expected to ameliorate disease symptoms. 2 0 -O-methoxyethyl phosphorothioate (2OMoePS) AONs targeting splicing silencers (sequences bound by splicing factors that induce exon exclusion) have been identified that can improve exon 7 inclusion (Hua et al., 2008) (Figure 1F ). As spinal muscular atrophy is primarily caused by loss of motor neurons and typical AONs do not cross the blood-brain barrier, delivery into the central nervous system was thought to be required. Postnatal intraventricular AON injections indeed improved survival from 10 to 16 days in a severe mouse model (Hua et al., 2011) . However, when these mice were injected subcutaneously with high doses of AON, a median survival of 108 days could be achieved, whereas combined subcutaneous and intraventricular treatment improved this to 173 days. This implies that, at least in mice, restoration of SMN, which is involved in small nuclear ribonucleoprotein particle biogenesis, in other tissues is crucial for improving survival. Exon 7 inclusion and expression of SMN protein was increased in the spinal cord, brain, liver, heart, kidneys, and skeletal muscles. Treated animals were generally smaller, weighed less, and had shorter tails than heterozygous littermates, but most could climb and run and exhibited improved strength and normal neuromuscular junctions.
Bifunctional AONs have also been tested as a way to improve SMN2 exon 7 inclusion (Osman et al., 2011) . A 2OMePS AON targeting an intronic splicing silencer in intron 7 can be modified with an oligonucleotide tail that recruits exon inclusion factors, further enabling exon 7 recognition and inclusion into SMN2 transcripts. Tailed AONs induced more exon 7 inclusion and higher SMN protein levels in patient-derived cells and a mouse model than did regular AONs. Intraventricular treatment with both the nontailed and tailed AONs modestly increased survival, with the tailed AONs again outperforming the regular AONs. A putative disadvantage of this approach is that tailed AONs are relatively long, which may hamper tissue uptake upon systemic treatment.
Familial dysautonomia is an autosomal recessive, congenital sensory neuropathy caused by aberrant splicing of the IKBKAP gene, leading to reduced levels of the ikappaB kinase complex associated protein (IKAP) that potentially causes IKAP protein levels to drop below the amount required for normal development and differentiation. Nearly all patients are homozygous for a mutation in intron 20 leading to the frequent skipping of exon 20 in the IKAP transcript. IKAP has many functions, including transcriptional elongation of genes involved in cell migration and adhesion, and complete lack of IKAP is embryonic lethal. Interestingly, exon 20 inclusion could be improved in a mouse model containing a BAC with the mutated human IKBKAP gene using kinetin, a plant cytokine, via an as yet unidentified mechanism (Shetty et al., 2011) . Daily oral treatment (either by gavage or in food) was tolerated well by the mice, and pharmacokinetic studies confirmed that kinetin was able to pass the blood-brain barrier. Exon 20 inclusion and IKAP protein levels were increased in all tissues analyzed, and kinetin treatment in primary neuronal cells derived from this mouse model showed a dose-dependent increase of exon 20 inclusion and protein levels. The fact that kinetin can be delivered orally facilitates its clinical development, although it is not yet known whether increasing levels of IKAP will be therapeutic in patients, as part of the neurodegeneration is already present at birth and may therefore be irreversible. Nevertheless, such treatment may still halt or slow further neurodegeneration. Kinetin has also been shown to improve exon inclusion in mutated neurofibromin 1 transcripts and may therefore be more widely applicable (Pros et al., 2010) . It has not yet been investigated whether kinetin treatment also influences splicing of other genes in a detrimental manner; so far, the treatment appears to be well tolerated by mice.
Perspective
Taken together, these recent results underscore that therapeutic splicing modulation with chemical compounds or AONs has great potential for treating many diseases. It has reached phase 3 clinical trial for DMD and might become clinically applicable for this disease in the near future. Certainly, there are hurdles that still must be overcome such as improved delivery and specificity; nevertheless, splicing modulation offers hope for combating many genetic diseases that are currently untreatable.
